Second-generation COVID-19 vaccine

First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.

Partner with us to speed up the development of a Phase 2 clinical trial-ready second-generation vaccine which induces durable and strong neutralising antibody response through direct investment or licensing.

The innovation

Second-generation COVID-19 vaccine which induces durable and strong neutralising antibody immunity activity against the original Wuhan SARS-CoV-2 strain as well as Beta, Delta and Omicron variants.

Market need

Safe and effective vaccines are critical in controlling the spread of COVID-19, which has claimed more than six million lives. Emerging mutant variants of SARS-CoV-2 are less susceptible to the immunity produced by the first generation COVID-19 vaccines.

Innovation status

The second-generation vaccine targets the receptor-binding domain region of the spike protein, compared to current vaccines that use antigens based on the full-length spike protein. This approach offers potential production and manufacturing advantages including the delivery of abundant, temperature-stable vaccine doses at an affordable cost.



Download flyer for more information (PDF, 845 KB)